Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM PRESERVATIVE FREE versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
HEPARIN SODIUM PRESERVATIVE FREE vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, as well as factors IXa, XIa, and XIIa. This inhibits clot formation and propagation.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Initial bolus of 80 units/kg IV, followed by continuous infusion at 18 units/kg/hour IV; adjusted to maintain aPTT of 1.5-2.5 times control.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
Terminal half-life is 0.5–2.5 hours (mean ~1.5 h) after IV administration; dose-dependent due to saturable clearance. At therapeutic doses, half-life averages 1–2 hours.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Primarily renal; small amounts in urine as unchanged drug and metabolites. Biliary/fecal elimination is negligible (<5%).
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category A/B
Category C
Anticoagulant
Anticoagulant